期刊
ONCOLOGY RESEARCH AND TREATMENT
卷 45, 期 1-2, 页码 4-9出版社
KARGER
DOI: 10.1159/000520561
关键词
Metastatic breast cancer; Circulating tumor cell; Circulating tumor DNA; Liquid biopsy; Therapy interventions
类别
Blood-based diagnostics, including the detection of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), have shown potential in improving prognosis assessment and therapy choices for metastatic breast cancer (MBC). High CTC counts have been confirmed as an independent prognostic factor, and interventions guided by liquid biopsy have shown promising results. However, the prognostic value of ctDNA and the optimal therapeutic options for patients with persistently high CTC numbers still require further investigation.
Background: In metastatic breast cancer (MBC), blood-based diagnostics have become a major focus of oncological research in the last 2 decades. Detection of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) has the potential to improve prognosis assessment and complement standard therapy monitoring tools. Summary: To date, several large analyses have confirmed high CTC counts as an independent prognostic factor. Persistently high CTC numbers during systemic treatment are associated with early progression, but it remains to be clarified which therapeutic options should be offered to such patients since the SWOG 0500 trial failed to show benefit from early switch to another chemotherapy regimen in patients with CTC persistence. In comparison, evidence on the prognostic value of ctDNA is still limited. Most importantly, liquid biopsy-guided treatment interventions have been investigated in several trials. In patients with hormone receptor-positive and HER2-negative MBC, CTC-driven therapy choices resulted in similar PFS to physician's choice treatment. Recently, the DETECT III trial has shown that patients with HER2-negative MBC and HER2-positive CTCs may benefit from targeted anti-HER2 treatment with lapatinib. ctDNA-driven therapy selection has already been approved in clinical routine: alpelisib is the first targeted treatment indicated on the basis of a ctDNA test. Key Messages: CTCs and ctDNA predict clinical outcome and have a potential to improve therapy choices in MBC. (c) 2021 The Author(s). Published by S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据